Skip to content
Insider tapeLive · 5:07 PM ET
My stocks

BridgeBio Oncology Therapeutics (BBOT) insider trading

Insider activity, historical context and SEC filings · data through Nov 20, 2026

BBOT

Latest price · Nov 20, 2026 $1.82 -2.2% on the day · -85.1% over 12 months 52-week range $1.80 – $13.69
Get BBOT alerts
Open-market purchases0 insidersno buys · last 12 months
Insiders selling2last 12 months
Reported sales$4K2 of 2 recent sales pre-planned (10b5-1)
In 15 seconds

No open-market insider buying in the last 12 months. Selling alone is common (taxes, diversification, pre-planned 10b5-1 sales) and isn't treated as a signal here.

Label: Net selling · based on open-market trades (codes P and S), last 12 months. Not a rating or advice.
  • Next earnings expected around Feb 9, 2027 (estimate from past release dates). Insiders usually trade in the weeks after results; past reactions ↓
Latest open-market trade

Sale Pedro Beltran, CEO, President sold 1,870 shares at $1.84 ($3K).

Trade date
Nov 18, 2026
Disclosed to the SEC
Nov 20, 2026
Type
Pre-planned sale, 10b5-1 (code S)

Read the original SEC filing ↗All BBOT insider trades ↓

Insiders have two business days to report a trade to the SEC, so filings (and our alerts) always come after the trade, never in real time.

BBOT insider transactions (Form 4)

Open-market purchases and sales.

Filed Insider Type Shares Price Value Since Score
Nov 20 NewSEC Pedro BeltranCEO, President Sell Plan 1,87041,659 held (−4%) $1.84 $3K -1.2% —
Nov 17SEC Marc CoboPrincipal Accounting Officer Sell Plan 7813,734 held (−1%) $2.37 $185 -23.2% —
Historical context

Similar past setups: not applicable. BBOT has had no open-market insider purchases in the last 12 months, so there's no buying setup to compare with history. When insiders buy, this section shows how 6,290 similar past buys did over 90 days. How we calculate this →

Play with BBOT in the Research Lab

BBOT has no open-market insider buys in the last 12 months. Try the tools with any setup.

All tools →

Quick backtest: did buys like this beat the market?

Insiders buying
CEO or CFO
Dollar size
Stock before

Tap a setting to see how 6,290 past insider buys did.

Open the full Backtester →

Share price and insider trades

BBOT closeInsider buyInsider sale
051015DecJan 2026FebMarAprMayJunJulAugSepOctNovEEarnings release filed 2026-03-05EEarnings release filed 2026-05-12EEarnings release filed 2026-08-11EEarnings release filed 2026-11-10Sold $185 on 2026-11-13 · Marc CoboSold $3,443 on 2026-11-18 · Pedro Beltran
Bought, 12 months$0
Sold, 12 months$4K
Insiders buying0
Insiders selling2

BridgeBio Oncology Therapeutics insider trading at a glance (Nov 20, 2026): in the past 12 months, 0 insiders bought $0 and 2 sold $4K of BBOT stock on the open market.

By InsiderPrint Research Desk · Updated · Sources: SEC EDGAR Form 4 filings · How we calculate this

BBOT insider buying and selling by quarter

Open-market purchases (green, above the line) and sales (red, below), by trade date.

Q4 2026: $4K sold (2 trades)Q4 2026
QuarterBoughtPurchasesSoldSales
Q4 2026—0$4K2

Valuation, profit and volume

Volume vs. 50-day0.8×Last 5 sessions

Valuation figures for BBOT are refreshed each weekday; some aren't published for every company. Volume and paper profit use daily closing prices.

Summary

Over the past 12 months, 0 BridgeBio Oncology Therapeutics, Inc. insiders reported open-market purchases totaling $0, while 2 insiders reported sales totaling $4K. 2 of 2 recorded sales were made under pre-scheduled Rule 10b5-1 trading plans, which are usually less informative than discretionary sales.

BBOT earnings: how the stock reacted

Each quarterly results release (SEC 8-K Item 2.02), the trend before it, insider trades in the 30 days before, and the 2-day market reaction. “E” marks releases on the chart above.

Does it matter? →
Release15 days beforeInsiders, 30 days beforeReaction (2 days)Next 30 days
Nov 10, 2026 -13.5% None +11.3%S&P +0.9% pending
Aug 11, 2026 +5.2% None +1.5%S&P -0.1% -47.5%
May 12, 2026 -10.1% None +2.4%S&P +0.4% -4.1%
Mar 5, 2026 -4.6% None +2.5%S&P -1.9% -14.5%
Nov 12, 2025 +12.7% None -2.9%S&P -1.6% +1.7%

Most companies bar insiders from trading in the weeks before results, so pre-earnings purchases are rare and often made by directors or under pre-set plans. Past reactions don't predict future ones.

Insiders at BridgeBio Oncology Therapeutics, Inc.

InsiderBoughtSoldLast filingPast buys beat S&PScore
Pedro BeltranCEO, President — $3K Nov 20, 2026 — —
Marc CoboPrincipal Accounting Officer — $185 Nov 17, 2026 — —

BBOT stock: common questions

Are BridgeBio Oncology Therapeutics, Inc. insiders buying BBOT stock?

No. No BridgeBio Oncology Therapeutics, Inc. insider reported an open-market purchase of BBOT in the past 12 months.

Are BridgeBio Oncology Therapeutics, Inc. insiders selling BBOT stock?

2 insiders reported sales worth $4K over the same period.

Where does this data come from?

Every transaction comes from Form 4 filings that insiders must submit to the SEC within two business days of a trade. We pull them from SEC EDGAR every night.

What is BBOT's 52-week range?

Over the past year BBOT has traded between $1.80 and $13.69. It last closed at $1.82 on Nov 20, 2026.